|
| General Information |
| Business: |
We are a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets. Our primary focus is to obtain approval for the sale of Trevyent® for the treatment of pulmonary arterial hypertension, or PAH. We are also developing two product candidates for the treatment of post-surgical and acute pain in the home setting. Our product candidates are enabled by our proprietary PatchPump®, which is a discreet, water-resistant and disposable drug administration technology. Our PatchPump technology is aseptically pre-filled with sterile liquid drug at the site of manufacture and pre-programmed to deliver an accurate, steady flow of drug to a patient, either subcutaneously or intravenously. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
22 |
Founded: |
2005 |
|
| Contact Information |
| Address: |
5 Oppenheimer Street, Rehovot, Israel 7670105 |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -19.0 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
STDY |
| Shares (millions): |
4.7 |
| Price Range: |
$8.50 - $8.50 |
| Est.$ Volume |
$ 40.0 mil |
| Manager / Joint Managers |
Wells Fargo Securities/ RBC Capital Markets |
| Co Managers |
JMP Securities |
| Expected to Trade |
3/20/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
